Clinical trial
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral…
NCT00478595 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00478595 |
|---|---|
| Title | Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-diabetic Drug |
| Acronym | SYMPHONY |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity, Diabetes Mellitus Type 2 |
| Intervention type | Drug |
| Interventions | Rimonabant, Placebo (for Rimonabant), Anti-diabetic monotherapy |
| Enrollment | 458 |
| Start date | Apr 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | May 25, 2007 |
| Last update posted | Jun 6, 2016 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: